Cargando…
Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma
Primary hepatocellular carcinoma (HCC) is one of the most frequently occurring pernicious tumors in the world. It is typically very insidious in the early stages with no obvious symptoms. Its development and metastasis are very rapid. Upon diagnosis, most patients have already reached a local advanc...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755348/ https://www.ncbi.nlm.nih.gov/pubmed/33376710 http://dx.doi.org/10.2147/JHC.S272762 |
_version_ | 1783626335771426816 |
---|---|
author | Zong, Jingjing Fan, Zhe Zhang, Yewei |
author_facet | Zong, Jingjing Fan, Zhe Zhang, Yewei |
author_sort | Zong, Jingjing |
collection | PubMed |
description | Primary hepatocellular carcinoma (HCC) is one of the most frequently occurring pernicious tumors in the world. It is typically very insidious in the early stages with no obvious symptoms. Its development and metastasis are very rapid. Upon diagnosis, most patients have already reached a local advanced stage or have established distant metastases. The treatment of HCC is limited, with poor prognosis and short natural survival time. In order to improve the efficiency of early diagnosis, it is particularly significant to choose economic and effective diagnosis methods. Ultrasound, magnetic resonance imaging, and computed tomography are usually used in the clinic, but these methods are extremely limited in the diagnosis of HCC. Tumor markers have become the main effective early clinical diagnosis method. Potential serum tumor markers include alpha fetoprotein heterogeneity, Golgi protein 73, phosphatidylinositol proteoglycan (GPC-3), osteopontin, abnormal prothrombin, and heat shock protein. These tumor markers provide new ideas and methods for the diagnosis of HCC. A combination of multiple markers can make up for the deficiency of single marker detection and provide a new strategy for the prognosis and auxiliary diagnosis of HCC. This review introduces protein tumor markers utilized over the past five years. |
format | Online Article Text |
id | pubmed-7755348 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-77553482020-12-28 Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma Zong, Jingjing Fan, Zhe Zhang, Yewei J Hepatocell Carcinoma Review Primary hepatocellular carcinoma (HCC) is one of the most frequently occurring pernicious tumors in the world. It is typically very insidious in the early stages with no obvious symptoms. Its development and metastasis are very rapid. Upon diagnosis, most patients have already reached a local advanced stage or have established distant metastases. The treatment of HCC is limited, with poor prognosis and short natural survival time. In order to improve the efficiency of early diagnosis, it is particularly significant to choose economic and effective diagnosis methods. Ultrasound, magnetic resonance imaging, and computed tomography are usually used in the clinic, but these methods are extremely limited in the diagnosis of HCC. Tumor markers have become the main effective early clinical diagnosis method. Potential serum tumor markers include alpha fetoprotein heterogeneity, Golgi protein 73, phosphatidylinositol proteoglycan (GPC-3), osteopontin, abnormal prothrombin, and heat shock protein. These tumor markers provide new ideas and methods for the diagnosis of HCC. A combination of multiple markers can make up for the deficiency of single marker detection and provide a new strategy for the prognosis and auxiliary diagnosis of HCC. This review introduces protein tumor markers utilized over the past five years. Dove 2020-12-18 /pmc/articles/PMC7755348/ /pubmed/33376710 http://dx.doi.org/10.2147/JHC.S272762 Text en © 2020 Zong et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Zong, Jingjing Fan, Zhe Zhang, Yewei Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma |
title | Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma |
title_full | Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma |
title_fullStr | Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma |
title_full_unstemmed | Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma |
title_short | Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma |
title_sort | serum tumor markers for early diagnosis of primary hepatocellular carcinoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755348/ https://www.ncbi.nlm.nih.gov/pubmed/33376710 http://dx.doi.org/10.2147/JHC.S272762 |
work_keys_str_mv | AT zongjingjing serumtumormarkersforearlydiagnosisofprimaryhepatocellularcarcinoma AT fanzhe serumtumormarkersforearlydiagnosisofprimaryhepatocellularcarcinoma AT zhangyewei serumtumormarkersforearlydiagnosisofprimaryhepatocellularcarcinoma |